Solid organ transplantation is an established treatment method for individuals with end-stage organ dysfunction. However, despite the common perception that transplantation offers a lasting cure, transplant recipients have limited long-term treatment options for chronic rejection. Transplant vasculopathy is recognized as one of the defining pathological indicators of chronic rejection, characterized by diffuse intimal wall thickening compromising vessel function, and, in severe cases, leads to allograft failure. While the increasing number of solid organ transplants reflects the modern advancements in treating end-stage organ dysfunction, it also highlights the continuing challenge of understanding and developing effective therapies for managing chronic rejection.